{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:01:37Z","timestamp":1793714497247,"version":"4.6.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Anesthesiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The anticoagulant treatment and clinical efficacy of heparin in sepsis remains controversial. We conducted a meta-analysis to estimate the clinical efficacy of unfractionated heparin (UFH) in adult septic patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>A systematic review of Medline, Cochrane Library, PubMed, Embase, WEIPU database, CNKI database, WANFANG database was performed from inception to January 2021. We included Randomized controlled trials (RCTs) and the main outcome was 28 d mortality. Data analysis was performed with Review Manager (RevMan) version 5.3 software. The meta-analysis included 2617 patients from 15 RCTs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Comparing to control group, UFH could reduce 28 d mortality (RR: 0.82; 95% CI: 0.72 to 0.94) especially for patient with Acute Physiology and Chronic Health Evaluation II (APACHE II)\u2009&gt;\u200915, (RR: 0.83; 95% CI: 0.72 to 0.96). In UFH group, the platelet (PLT) (MD: 9.18; 95% CI: 0.68 to 17.68) was higher, the activated partial thromboplastin time (APTT) was shorter (MD: -8.01; 95% CI: \u2212\u200913.84 to \u2212\u20092.18) and the prothrombin time (PT) results (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05) failed to reach statistical significance. UFH decreased multiple organ dysfunction syndrome (MODS) incidence (RR: 0.61; 95% CI: 0.45 to 0.84), length of stay (LOS) in ICU (MD: -4.94; 95% CI: \u2212\u20096.89 to \u2212\u20092.99) and ventilation time (MD: -3.01; 95% CI: \u2212\u20094.0 to \u2212\u20092.02). And UFH had no adverse impact on bleeding (RR: 1.10; 95% CI: 0.54 to 2.23).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This meta-analysis suggests that UFH may reduce 28 d mortality and improve the clinical efficacy in sepsis patients without bleeding adverse effect.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12871-021-01545-w","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T08:02:49Z","timestamp":1642752169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Unfractionated heparin improves the clinical efficacy in adult sepsis patients: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Sifeng","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"issue":"8","key":"1545_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA."},{"issue":"6","key":"1545_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.23736\/S0375-9393.18.12782-9","volume":"85","author":"A Boscolo","year":"2019","unstructured":"Boscolo A, Campello E, Bertini D, et al. Levels of circulating microparticles in septic shock and sepsis-related complications: a case-control study. Minerva Anestesiol. 2019;85(6):625\u201334.","journal-title":"Minerva Anestesiol"},{"issue":"3","key":"1545_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.4097\/kja.19396","volume":"73","author":"A Boscolo","year":"2020","unstructured":"Boscolo A, Spiezia L, Campello E, et al. Whole-blood hypocoagulable profile correlates with a greater risk of death within 28 days in patients with severe sepsis. Korean J Anesthesiol. 2020;73(3):224\u201331.","journal-title":"Korean J Anesthesiol"},{"issue":"11","key":"1545_CR4","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1055\/s-0039-1693740","volume":"119","author":"K Yamakawa","year":"2019","unstructured":"Yamakawa K, Gando S, Ogura H, Umemura Y, Kabata D, Shintani A, et al. Identifying sepsis populations benefitting from anticoagulant therapy: a prospective cohort study incorporating a restricted cubic spline regression model. Thromb Haemost. 2019;119(11):1740\u201351.","journal-title":"Thromb Haemost"},{"issue":"6","key":"1545_CR5","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jamacardio.2016.2181","volume":"1","author":"AJ Walkey","year":"2016","unstructured":"Walkey AJ, Quinn EK, Winter MR, McManus DD, Benjamin EJ. Practice patterns and outcomes associated with use of anticoagulation among patients with atrial fibrillation during sepsis. JAMA Cardiol. 2016;1(6):682\u201390.","journal-title":"JAMA Cardiol"},{"key":"1545_CR6","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nm.2184","volume":"16","author":"S Massberg","year":"2010","unstructured":"Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med. 2010;16:887\u201396.","journal-title":"Nat Med"},{"issue":"3","key":"1545_CR7","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","volume":"43","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304\u201377.","journal-title":"Intensive Care Med"},{"key":"1545_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ams2.322","volume":"5","author":"O Nishida","year":"2018","unstructured":"Nishida O, Ogura H, Egi M, et al. The Japanese clinical practice guidelines for management of sepsis and septic shock 2016 (J-SSCG 2016). Acute Med Surg. 2018;5:3\u201389.","journal-title":"Acute Med Surg"},{"key":"1545_CR9","unstructured":"World Health Organization (WHO). https:\/\/app.magicapp.org\/#\/guideline\/j1WBYn. Accessed 25 Dec 2021."},{"key":"1545_CR10","doi-asserted-by":"crossref","unstructured":"Mu S, Liu Y, Jiang J, Ding R, Li X, Li X, et al. Unfractionated heparin ameliorates pulmonary microvascular endothelial barrier dysfunction via microtubule stabilization in acute lung injury. Respir Res. 2018;19(1):220.","DOI":"10.1186\/s12931-018-0925-6"},{"key":"1545_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jss.2019.01.020","volume":"238","author":"YN Liu","year":"2019","unstructured":"Liu YN, Mu S, Li X, et al. Unfractionated heparin alleviates sepsis-induced acute lung injury by protecting tight junctions. J Surg Res. 2019;238:175\u201385.","journal-title":"J Surg Res"},{"issue":"7","key":"1545_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1089\/jir.2018.0042","volume":"38","author":"X Li","year":"2018","unstructured":"Li X, Zhao EF, Li L, et al. Unfractionated heparin modulates lipopolysaccharide induced cytokine production by different signaling pathways in THP-1 cells. J Interf Cytokine Res. 2018;38(7):283\u20139.","journal-title":"J Interf Cytokine Res"},{"issue":"5","key":"1545_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/s13054-014-0563-4","volume":"18","author":"C Wang","year":"2014","unstructured":"Wang C, Chi C, Guo L, Wang X, Guo L, Sun J, et al. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Crit Care. 2014;18(5):563.","journal-title":"Crit Care"},{"issue":"3","key":"1545_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/CCM.0000000000000763","volume":"43","author":"R Zarychanski","year":"2015","unstructured":"Zarychanski R, Abou-Setta AM, Kanji S, Turgeon AF, Kumar A, Houston DS, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Crit Care Med. 2015;43(3):511\u20138.","journal-title":"Crit Care Med"},{"key":"1545_CR15","doi-asserted-by":"publisher","first-page":"25984","DOI":"10.1038\/srep25984","volume":"6","author":"Y Fan","year":"2016","unstructured":"Fan Y, Jiang M, Gong D, Zou C. Efficacy and safety of low-molecular-weight heparin in patients with sepsis: a meta-analysis of randomized controlled trials. Sci Rep. 2016;6:25984.","journal-title":"Sci Rep"},{"key":"1545_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ."},{"key":"1545_CR17","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane","author":"I Boutron","year":"2019","unstructured":"Boutron I, Page MJ, Higgins JPT, Altman DG, Lundh A, Hr\u00f3bjartsson A. Chapter 7: considering bias and conflicts of interest among the included studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane; 2019. Available from www.training.cochrane.org\/handbook."},{"key":"1545_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane","author":"JPTSJ Higgins","year":"2019","unstructured":"Higgins JPTSJ, Page MJ, Elbers RG, Sterne JAC. Chapter 8: assessing risk of bias in a randomized trial. In: Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane; 2019. Available from www.training.cochrane.org\/handbook."},{"key":"1545_CR19","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane","author":"JJ Deeks","year":"2019","unstructured":"Deeks JJ, Higgins JPT, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane; 2019. Available from www.training.cochrane.org\/handbook."},{"key":"1545_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"1545_CR21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ."},{"issue":"4","key":"1545_CR22","first-page":"377","volume":"26","author":"QM Deng","year":"2017","unstructured":"Deng QM, Chen AH, Shang D, Zhang YL, Li SW, Zhang GR. The effect of heparin on endothefial function and prognosis in sepsis shock. Chin J Emerg Med. 2017;26(4):377\u201380.","journal-title":"Chin J Emerg Med"},{"issue":"5","key":"1545_CR23","first-page":"46","volume":"33","author":"BHR Guli","year":"2014","unstructured":"Guli BHR. The clinical effect analysis of 21 patients with severe sepsis. China Foreign Med Treat. 2014;33(5):46\u20138.","journal-title":"China Foreign Med Treat"},{"issue":"3","key":"1545_CR24","first-page":"172","volume":"28","author":"ZS Guo","year":"2019","unstructured":"Guo ZS. Clinical observation of low dose heparin in therapy in stage DIC before sepsis and its effect on prognosis. Proc Clin Med. 2019;28(3):172\u20134.","journal-title":"Proc Clin Med"},{"issue":"7","key":"1545_CR25","first-page":"934","volume":"32","author":"YH Hou","year":"2011","unstructured":"Hou YH, Yao H, Song Y, Ding Z, Li Q. The therapeutic effect of low-dose heparin on early administration of patients with severe sepsis. An-hui Med J. 2011;32(7):934\u20136.","journal-title":"An-hui Med J"},{"issue":"4","key":"1545_CR26","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1097\/CCM.0b013e31819c06bc","volume":"37","author":"F Jaimes","year":"2009","unstructured":"Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D, et al. Unfractioned heparin for treatment of sepsis: a randomized clinical trial (the HETRASE study). Crit Care Med. 2009;37(4):1185\u201396.","journal-title":"Crit Care Med"},{"issue":"5","key":"1545_CR27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1164\/rccm.200612-1803OC","volume":"176","author":"M Levi","year":"2007","unstructured":"Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med. 2007;176(5):483\u201390.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1545_CR28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3892\/etm.2013.1466","volume":"7","author":"XL Liu","year":"2014","unstructured":"Liu XL, Wang XZ, Liu XX, Hao D, Jaladat Y, Lu F, et al. Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: a prospective clinical study. Exp Ther Med. 2014;7(3):604\u20138.","journal-title":"Exp Ther Med"},{"issue":"15","key":"1545_CR29","first-page":"917","volume":"29","author":"XL Liu","year":"2009","unstructured":"Liu XL, Lv CJ, Han ZD, Zhang XR, Li HB. Low-dose heparin on treatment of sepsis in hypercoagulable period. Int J Repair. 2009;29(15):917\u20139.","journal-title":"Int J Repair"},{"issue":"14","key":"1545_CR30","first-page":"94","volume":"23","author":"Y Peng","year":"2013","unstructured":"Peng Y. Effect and prognosis of early low-dose heparin on the sepsis patients in pre-DIC stage. Chin J Mod Med. 2013;23(14):94\u20136.","journal-title":"Chin J Mod Med"},{"issue":"8","key":"1545_CR31","first-page":"80","volume":"25","author":"MX Wang","year":"2012","unstructured":"Wang MX. Small dose of heparin to sepsis treatment action research. Med Inf. 2012;25(8):80\u20131.","journal-title":"Med Inf"},{"key":"1545_CR32","unstructured":"Wu HW, Ye PJ, Huang J, Feng YP. Clinical study on low-dose unfrnctlonmted heparin thempy for sepsis. Chin Med. 2011;6(1):89\u201391."},{"issue":"17","key":"1545_CR33","first-page":"1209","volume":"44","author":"XJ Zhang","year":"2006","unstructured":"Zhang XJ, Ma XC. Therapeutic effects of early administration of low-dose heparin in patients with severe sepsis. Chin J Surg. 2006;44(17):1209\u201311.","journal-title":"Chin J Surg"},{"issue":"7","key":"1545_CR34","first-page":"566","volume":"48","author":"C Zhao","year":"2009","unstructured":"Zhao C, Zhang ZD, Zhang XJ, Li X, Zhu R, Ma XC. Evaluation of clinical effects on low-dose heparin therapy for sepsis. Chin J Int Med. 2009;48(7):566\u20139.","journal-title":"Chin J Int Med"},{"issue":"11","key":"1545_CR35","first-page":"1120","volume":"32","author":"L Zhao","year":"2007","unstructured":"Zhao L, Xu YH, Li WF. Clinical observation of unfractioned heparin for preventive and therapeutic effects on severe sepsis. Med J Chia PLA. 2007;32(11):1120\u20131.","journal-title":"Med J Chia PLA"},{"issue":"3","key":"1545_CR36","first-page":"475","volume":"25","author":"K Zhang","year":"2016","unstructured":"Zhang K, Sun RQ, Li JX, Wang XW, Guo YH. Clinical observation of low dose heparin in sepsis treatment. Henan Med Res. 2016;25(3):475\u20136.","journal-title":"Henan Med Res"},{"key":"1545_CR37","unstructured":"The National library of medicine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02654561. Accessed 25 Dec 2021."},{"issue":"6","key":"1545_CR38","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/nicc.12401","volume":"24","author":"M Bahtouee","year":"2019","unstructured":"Bahtouee M, Eghbali SS, Maleki N, Rastgou V, Motamed N. Acute physiology and chronic health evaluation II score for the assessment of mortality prediction in the intensive care unit: a single-centre study from Iran. Nurs Crit Care. 2019;24(6):375\u201380.","journal-title":"Nurs Crit Care"},{"issue":"2","key":"1545_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1089\/jamp.2016.1317","volume":"30","author":"FE Van den Boogaard","year":"2017","unstructured":"Van den Boogaard FE, Hofstra JJ, Brands X, et al. Nebulized recombinant human tissue factor pathway inhibitor attenuates coagulation and exerts modest anti-inflammatory effects in rat models of lung injury. J Aerosol Med Pulm Drug Deliv. 2017;30(2):91\u20139.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"9_suppl","key":"1545_CR40","doi-asserted-by":"publisher","first-page":"8S","DOI":"10.1177\/1076029618806424","volume":"24","author":"C Papageorgiou","year":"2018","unstructured":"Papageorgiou C, Jourdi G, Adjambri E, et al. Disseminated intravascular coagulation: An update on pathogenesis, diagnosis, and therapeutic strategies. Clin Appl Thromb Hemost. 2018;24(9_suppl):8S\u201328S.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"1545_CR41","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/jth.12868","volume":"13","author":"M Levi","year":"2015","unstructured":"Levi M. Recombinant soluble thrombomodulin: coagulation takes another chance to reduce sepsis mortality. J Thromb Haemost. 2015;13(4):505\u20137.","journal-title":"J Thromb Haemost"},{"issue":"20","key":"1545_CR42","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2019.5358","volume":"321","author":"JL Vincent","year":"2019","unstructured":"Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, et al. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial. JAMA. 2019;321(20):1993\u20132002.","journal-title":"JAMA."},{"issue":"3","key":"1545_CR43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/bjh.14885","volume":"179","author":"X Li","year":"2017","unstructured":"Li X, Ma X. The role of heparin in sepsis: much more than just an anticoagulant. Br J Haematol. 2017;179(3):389\u201398.","journal-title":"Br J Haematol"},{"issue":"6","key":"1545_CR44","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.thromres.2011.07.044","volume":"128","author":"RY Ding","year":"2011","unstructured":"Ding RY, Zhao DM, Guo RX, Zhang ZD, Ma XC. Treatment with unfractionated heparin attenuates coagulation and inflammation in endotoxemic mice. Thromb Res. 2011;128(6):e160\u20135.","journal-title":"Thromb Res"},{"issue":"10","key":"1545_CR45","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.imbio.2014.06.005","volume":"219","author":"X Li","year":"2014","unstructured":"Li X, Li X, Zheng Z, Liu YN, Ma XC. Unfractionated heparin suppresses lipopolysaccharide-induced monocyte chemoattractant protein-1 expression in human microvascular endothelial cells by blocking Kr\u00fcppel-like factor 5 and nuclear factor-\u03baB pathway. Immunobiology. 2014;219(10):778\u201385.","journal-title":"Immunobiology."},{"issue":"3","key":"1545_CR46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.imbio.2014.10.008","volume":"220","author":"X Li","year":"2015","unstructured":"Li X, Liu YN, Wang L, Li ZL, Ma XC. Unfractionated heparin attenuates LPS-induced IL-8 secretion via PI3K\/Akt\/NF-\u03baB signaling pathway in human endothelial cells. Immunobiology. 2015;220(3):399\u2013405.","journal-title":"Immunobiology."},{"issue":"2","key":"1545_CR47","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/aas.12418","volume":"59","author":"YN Sun","year":"2015","unstructured":"Sun YN, Zhang H, An X, Ma CL. Effect of unfractionated heparin on endothelial glycocalyx in a septic shock model. Acta Anaesthesiol Scand. 2015;59(2):160\u20139.","journal-title":"Acta Anaesthesiol Scand"},{"key":"1545_CR48","unstructured":"The National library of Medicine. https:\/\/clinicaltrials.gov\/show\/NCT03378466. Accessed 25 Dec 2021."}],"container-title":["BMC Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-021-01545-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12871-021-01545-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12871-021-01545-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T02:03:47Z","timestamp":1666577027000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcanesthesiol.biomedcentral.com\/articles\/10.1186\/s12871-021-01545-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1545"],"URL":"https:\/\/doi.org\/10.1186\/s12871-021-01545-w","relation":{},"ISSN":["1471-2253"],"issn-type":[{"value":"1471-2253","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"3 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There were no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}